Literature DB >> 33001416

Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures.

Katryna Pampuscenko1, Ramune Morkuniene2, Lukas Krasauskas3, Vytautas Smirnovas3, Taisuke Tomita4, Vilmante Borutaite2.   

Abstract

Recent data from various experimental models support the link between extracellular tau and neurodegeneration; however, the exact mechanisms by which extracellular tau or its modified forms or aggregates cause neuronal death remain unclear. We have previously shown that exogenously applied monomers and oligomers of the longest tau isoform (2N4R) at micromolar concentrations induced microglial phagocytosis of stressed-but-viable neurons in vitro. In this study, we investigated whether extracellular phosphorylated tau2N4R (p-tau2N4R), isoform 1N4R (tau1N4R) and K18 peptide can induce neuronal death or loss in primary neuronal-glial cell cultures. We found that p-tau2N4R at 30 nM concentration induced loss of viable neurons; however, 700 nM p-tau2N4R caused necrosis of both neurons and microglia, and this neuronal death was partially glial cell-dependent. We also found that extracellular tau1N4R oligomers, but not monomers, at 3 μM concentration caused neuronal death in mixed cell cultures: self-assembly tau1N4R dimers-tetramers induced neuronal necrosis and apoptosis, whereas Aβ-promoted tau1N4R oligomers caused glial cell-dependent loss of neurons without signs of increased cell death. Monomeric and pre-aggregated tau peptide containing 4R repeats (K18) had no effect in mixed cultures, suggesting that tau neurotoxicity might be dependent on N-terminal part of the protein. Taken together, our results show that extracellular p-tau2N4R is the most toxic form among investigated tau species inducing loss of neurons at low nanomolar concentrations and that neurotoxicity of tau1N4R is dependent on its aggregation state.

Entities:  

Keywords:  Alzheimer’s disease; Cell death; Microglia; Neurons; Tau protein; Tauopathy

Year:  2020        PMID: 33001416     DOI: 10.1007/s12035-020-02150-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  51 in total

1.  Interneuronal transfer of human tau between Lamprey central neurons in situ.

Authors:  Wonhee Kim; Sangmook Lee; Cheolwha Jung; Ambar Ahmed; Gloria Lee; Garth F Hall
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

3.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

Authors:  Katharina Buerger; Michael Ewers; Tuula Pirttilä; Raymond Zinkowski; Irina Alafuzoff; Stefan J Teipel; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Hilkka Soininen; Harald Hampel
Journal:  Brain       Date:  2006-09-29       Impact factor: 13.501

4.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Authors:  Yuan Yuan Hu; Shan Shu He; Xiaochuan Wang; Qiu Hong Duan; Inge Grundke-Iqbal; Khalid Iqbal; Jianzhi Wang
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.

Authors:  Che-Chuan Yang; Ming-Jang Chiu; Ta-Fu Chen; Hui-Ling Chang; Bing-Hsien Liu; Shieh-Yueh Yang
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease.

Authors:  Philipp A Thomann; Elmar Kaiser; Peter Schönknecht; Johannes Pantel; Marco Essig; Johannes Schröder
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

7.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

Review 9.  Tau Secretion: Good and Bad for Neurons.

Authors:  Camille Pernègre; Antoine Duquette; Nicole Leclerc
Journal:  Front Neurosci       Date:  2019-06-26       Impact factor: 4.677

Review 10.  Biomarkers for tau pathology.

Authors:  Michael Schöll; Anne Maass; Niklas Mattsson; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; William Jagust
Journal:  Mol Cell Neurosci       Date:  2018-12-07       Impact factor: 4.314

View more
  5 in total

Review 1.  The propagation mechanisms of extracellular tau in Alzheimer's disease.

Authors:  Yun Wei; Meixia Liu; Dongxin Wang
Journal:  J Neurol       Date:  2021-04-28       Impact factor: 4.849

Review 2.  Tau Oligomers Neurotoxicity.

Authors:  Grazyna Niewiadomska; Wiktor Niewiadomski; Marta Steczkowska; Anna Gasiorowska
Journal:  Life (Basel)       Date:  2021-01-06

3.  The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration.

Authors:  Mar Puigdellívol; Stefan Milde; Anna Vilalta; Tom O J Cockram; David H Allendorf; Jeffrey Y Lee; Jacob M Dundee; Katryna Pampuščenko; Vilmante Borutaite; Hugh N Nuthall; Jack H Brelstaff; Maria Grazia Spillantini; Guy C Brown
Journal:  Cell Rep       Date:  2021-12-28       Impact factor: 9.423

Review 4.  Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis.

Authors:  Toshihiko Tashima
Journal:  Pharmaceutics       Date:  2022-02-14       Impact factor: 6.321

Review 5.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.